Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

352 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder.
Recourt K, de Boer P, Zuiker R, Luthringer R, Kent J, van der Ark P, Van Hove I, van Gerven J, Jacobs G, van Nueten L, Drevets W. Recourt K, et al. Among authors: drevets w. Transl Psychiatry. 2019 Sep 3;9(1):216. doi: 10.1038/s41398-019-0553-z. Transl Psychiatry. 2019. PMID: 31481683 Free PMC article. Clinical Trial.
Correction to: The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder.
Recourt K, de Boer P, Zuiker R, Luthringer R, Kent J, van der Ark P, Van Hove I, van Gerven J, Jacobs G, van Nueten L, Drevets W. Recourt K, et al. Among authors: drevets w. Transl Psychiatry. 2019 Oct 2;9(1):240. doi: 10.1038/s41398-019-0585-4. Transl Psychiatry. 2019. PMID: 31578318 Free PMC article.
Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial.
Recourt K, van der Aart J, Jacobs G, de Kam M, Drevets W, van Nueten L, Kanhai K, Siebenga P, Zuiker R, Ravenstijn P, Timmers M, van Gerven J, de Boer P. Recourt K, et al. Among authors: drevets w. J Psychopharmacol. 2020 Sep;34(9):1030-1042. doi: 10.1177/0269881120914206. Epub 2020 Apr 4. J Psychopharmacol. 2020. PMID: 32248747 Clinical Trial.
The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia.
Brooks S, Jacobs GE, de Boer P, Kent JM, Van Nueten L, van Amerongen G, Zuiker R, Kezic I, Luthringer R, van der Ark P, van Gerven JM, Drevets W. Brooks S, et al. Among authors: drevets w. J Psychopharmacol. 2019 Feb;33(2):202-209. doi: 10.1177/0269881118822258. Epub 2019 Jan 15. J Psychopharmacol. 2019. PMID: 30644312 Clinical Trial.
A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity.
De Boer P, Drevets WC, Rofael H, van der Ark P, Kent JM, Kezic I, Parapatics S, Dorffner G, van Gerven J, Beneš H, Keicher C, Jahn H, Seiden DJ, Luthringer R. De Boer P, et al. J Psychopharmacol. 2018 Jun;32(6):668-677. doi: 10.1177/0269881118773745. Epub 2018 May 31. J Psychopharmacol. 2018. PMID: 29848147 Clinical Trial.
Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans.
Salvadore G, Bonaventure P, Shekhar A, Johnson PL, Lord B, Shireman BT, Lebold TP, Nepomuceno D, Dugovic C, Brooks S, Zuiker R, Bleys C, Tatikola K, Remmerie B, Jacobs GE, Schruers K, Moyer J, Nash A, Van Nueten LGM, Drevets WC. Salvadore G, et al. Transl Psychiatry. 2020 Sep 7;10(1):308. doi: 10.1038/s41398-020-00937-9. Transl Psychiatry. 2020. PMID: 32895369 Free PMC article.
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.
Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, Pinter C, Murrough JW, Sanacora G, Shelton RC, Kurian B, Winokur A, Fava M, Manji H, Drevets WC, Van Nueten L. Singh JB, et al. Among authors: drevets wc. Am J Psychiatry. 2016 Aug 1;173(8):816-26. doi: 10.1176/appi.ajp.2016.16010037. Epub 2016 Apr 8. Am J Psychiatry. 2016. PMID: 27056608 Clinical Trial.
352 results